Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

Recursion Pharmaceuticals Inc (RXRX) showcases strong financial management and strategic partnerships while navigating challenges in drug discovery.

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...